In summary, our transcriptome-based survival analysis identified the expression profile of MAP4K4 as a significant independent predictor of prognosis for MSI-GC, being associated with TME composition and modulation of known cancer-associated pathways, like EMT, which highlights its potential as a therapeutic target. This evidence concerns the gene MAP4K4 and cancer.